Journal article
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies
Clinics in liver disease, v 26(4), pp 705-726
Nov 2022
PMID: 36270725
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Primary biliary cholangitis (PBC) is an autoimmune disease of the interlobular bile ducts leading to secondary damage of hepatocytes and may progress to cirrhosis and liver failure. The first-line treatment is ursodeoxycholic acid; up to 40% of patients do not have an adequate response and remain at risk of disease progression. Obeticholic acid has been conditionally approved for the treatment of PBC as add-on therapy and bezafibrate has shown similar efficacy in this group of patients. Several new therapies are in development and may further add to the treatment options available to patients with PBC.
Metrics
Details
- Title
- Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies
- Creators
- Chung-Heng Liu - Drexel UniversityChristopher L Bowlus - University of California, Davis
- Publication Details
- Clinics in liver disease, v 26(4), pp 705-726
- Number of pages
- 22
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000877183600011
- Scopus ID
- 2-s2.0-85138093096
- Other Identifier
- 991021861168604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Gastroenterology & Hepatology